Published in Vaccine Weekly, March 5th, 2003
"Here we show that peripheral treatment with an agent that has high affinity for A-beta (gelsolin or GM1) but that is unrelated to an antibody or immune modulator reduced the level of A-beta in the brain, most likely because of a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly